Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.

International Journal of Cancer. Journal International Du Cancer
Seung Hyun OhHo-Young Lee

Abstract

Overexpression of insulin-like growth factor binding protein (IGFBP)-3 induces apoptosis of cancer cells. However, preexisting resistance to IGFBP-3 could limit its antitumor activities. This study characterizes the efficacy and mechanism of the combination of recombinant IGFBP-3 (rIGFBP-3) and HDAC inhibitors to overcome IGFBP-3 resistance in a subset of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) cells. The effects of the combination of rIGFBP-3 and a number of HDAC inhibitors on cell proliferation and apoptosis were assessed in vitro and in vivo by using the MTT assay, a flow cytometry-based TUNEL assay, Western blot analyses and the NSCLC xenograft tumor model. Combined treatment with HDAC inhibitors and rIGFBP-3 had synergistic antiproliferative effects accompanied by increased apoptosis rates in a subset of NSCLC and HNSCC cell lines in vitro. Moreover, combined treatment with depsipeptide and rIGFBP-3 completely suppressed tumor growth and increased the apoptosis rate in vivo in H1299 NSCLC xenografts. Evidence suggests that HDAC inhibitors increased the half-life of rIGFBP-3 protein by blocking protein kinase C (PKC)-mediated phosphorylation and degradation of rIGFBP-3. In additi...Continue Reading

References

Apr 4, 1997·Molecular and Cellular Endocrinology·J A Coverley, R C Baxter
Feb 25, 1998·Biochemical and Biophysical Research Communications·M K BaeK W Kim
Dec 6, 2002·Endocrine Reviews·Sue M Firth, Robert C Baxter
Nov 7, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S SieslingUNKNOWN Working Group of The Netherlands Cancer Registry
Jul 2, 2004·Nature Reviews. Cancer·Michael N PollakSusan E Hankinson
Jul 13, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Riccarda GranataEzio Ghigo
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seung-Hyun OhHo-Young Lee
May 18, 2006·Journal of the National Cancer Institute·Michael J ThunEugenia E Calle
Nov 23, 2006·Nature Cell Biology·Shao-Chun WangMien-Chie Hung
Jun 15, 2007·Journal of the National Cancer Institute·Seung Hyun OhHo-Young Lee
Dec 7, 2007·British Journal of Pharmacology·F CondorelliP L Canonico
Jan 26, 2008·Journal of Dental Research·T YokotaS Suzuki
Oct 9, 2008·Current Opinion in Oncology·Min-Jung LeeJane B Trepel
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward

❮ Previous
Next ❯

Citations

Sep 17, 2013·Cancer Chemotherapy and Pharmacology·Vasiliki PettaKonstantinos Syrigos
May 13, 2015·European Journal of Medicinal Chemistry·Shalini BajajPartha Pratim Roy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.